DAX24.664 -1,0%Est505.973 -0,9%MSCI World4.343 -0,1%Top 10 Crypto10,12 -2,1%Nas25.806 -0,1%Bitcoin68.219 -1,6%Euro1,1726 ±-0,0%Öl103,4 +1,4%Gold4.692 +0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Infineon 623100 SAP 716460 Lufthansa 823212 AMD (Advanced Micro Devices) 863186 Siemens Energy ENER6Y Allianz 840400 NEL ASA A0B733 Deutsche Telekom 555750 Amazon 906866 Novo Nordisk A3EU6F Intel 855681 Commerzbank CBK100 Micron Technology 869020
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX verliert 25.000-Punkte-Marke letztlich aus dem Blick -- Wall Street letztlich in Rot -- Rheinmetall gewinnt mehr -- Peloton, Infineon, Vonovia, Siemens Healthineers, Arm, IonQ, Microsoft im Fokus
Top News
Helium-Engpass durch Iran-Krieg: Warum Chip-Aktien jetzt in den Fokus rücken Helium-Engpass durch Iran-Krieg: Warum Chip-Aktien jetzt in den Fokus rücken
Ausblick: Intesa Sanpaolo mit Zahlen zum abgelaufenen Quartal Ausblick: Intesa Sanpaolo mit Zahlen zum abgelaufenen Quartal
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Aurinia Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
12,89 EUR -0,90 EUR -6,53 %
BMN
15,14 USD -1,10 USD -6,77 %
BTT
finanzen.net zero
Aurinia Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.1,82 Mrd. EUR

KGV7,70Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1W7D4

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINCA05156V1022

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolAUPH

Aurinia Pharmaceuticals Aktien News

DatumMeistgelesen
BusinesswireAurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
BusinesswireAurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
BusinesswireAurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
BusinesswireAurinia to Participate in Upcoming Investor Healthcare Conferences
BusinesswireAurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
BusinesswireAurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
BusinesswireAurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
BusinesswireAurinia Submits IND Application to US Food & Drug Administration for AUR 200
BusinesswireAurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan
BusinesswireAurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNIS? (voclosporin) for Patients with Lupus Nephritis at ACR 2023
BusinesswireAurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNIS? for Managing Lupus Nephritis
BusinesswireAurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
BusinesswireAurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis
BusinesswireAurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
BusinesswireAurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital
BusinesswireAurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines
BusinesswireAurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
BusinesswireAurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023
BusinesswireAurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
BusinesswireAurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy
BusinesswireLUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone
BusinesswireAurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees
BusinesswireAurinia Announces 2023 Annual General Meeting Results
BusinesswireAurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference

Aurinia Pharmaceuticals News

Aurinia Pharmaceuticals News: auf dieser Seite finden Sie alle Aurinia Pharmaceuticals News und Nachrichten zur Aurinia Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Aurinia Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Aurinia Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.